{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.7","upperLimit":"40.6","value":"34.5"},{"groupId":"OG001","lowerLimit":"8.9","upperLimit":"17.4","value":"12.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"260"}],"units":"Participants"}],"description":"Percentage of participants with treatment-emergent infusion-related reactions were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received daratumumab intravenous infusion (Dara IV) 16 milligrams per kilogram (mg/kg) once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG000","title":"Daratumumab IV"},{"description":"Participants received daratumumab 1800 mg subcutaneous injection (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Units per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG001","title":"Daratumumab SC"}],"paramType":"NUMBER","populationDescription":"Safety population included all randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Percentage of Participants With Treatment-emergent Infusion-related Reactions (IRR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}